반응식
Cl.[O:2]=[C:3]1[N:7]([C:8]2[CH:17]=[CH:16][C:11]([C:12]([O:14][CH3:15])=[O:13])=[CH:10][CH:9]=2)[CH2:6][C:5]2([CH2:22][CH2:21][NH:20][CH2:19][CH2:18]2)[O:4]1.[Cl:23][C:24]1[CH:31]=[CH:30][C:27]([CH:28]=O)=[CH:26][C:25]=1[C:32]([F:35])([F:34])[F:33]>>[Cl:23][C:24]1[CH:31]=[CH:30][C:27]([CH2:28][N:20]2[CH2:21][CH2:22][C:5]3([O:4][C:3](=[O:2])[N:7]([C:8]4[CH:17]=[CH:16][C:11]([C:12]([O:14][CH3:15])=[O:13])=[CH:10][CH:9]=4)[CH2:6]3)[CH2:18][CH2:19]2)=[CH:26][C:25]=1[C:32]([F:33])([F:34])[F:35]참가 물질
3
실험 절차
The title compound was prepared from methyl 4-(2-oxo-1-oxa-3,8-diazaspiro[4.5]dec-3-yl)benzoate hydrochloride salt (50 mg, 0.153 mmol; Example 1, Step 2) and 4-chloro-3-trifluoromethylbenzaldehyde (38.3 mg, 0.184 mmol) following essentially the same procedure described in Step 1 of Example 7-6. The title compound was obtained as a yellow solid (73 mg) that was used without any further purification.
출처 및 근거
- ORD 기록
- ord-1d7f7087f57346fca989910a1edc6143
- 출처 데이터셋
- uspto-grants-2014_06
- 특허 번호
- US08742110B2
연결된 노트
불러오는 중…